Search Within

Melanoma Disease Management Team

Formats
  1. Journal Article (1604)
  2. Meeting Abstract (791)
  3. Book Section (104)
  4. Review (72)
  5. Editorial (58)
  6. Research Letter (45)
  7. Guidelines (26)
  8. Conference Paper (22)
  9. Correspondence (21)
  10. Miscellaneous (16)
  11. Book Whole (11)
Groups
  1. Department of Medicine (1690)
  2. Survivorship Research (1193)
  3. Solid Tumor Oncology Division (1052)
  4. Department of Pathology and Laboratory Medicine (957)
  5. Surgery (947)
  6. Melanoma and Immunotherapeutics Service (793)

More Groups

People
  1. Klaus Busam (698)
  2. Daniel Coit (543)
  3. Allan Halpern (401)
  4. Michael Postow (369)
  5. Alexander Shoushtari (247)
  6. Jedd Wolchok (222)

More People

Years
  1. 2025 (89)
  2. 2024 (138)
  3. 2023 (160)
  4. 2022 (167)
  5. 2021 (149)
  6. 2020 (142)

More Years

Publications
  1. Journal of Clinical Oncology (269)
  2. Annals of Surgical Oncology (221)
  3. Journal of the American Academy of Dermatology (123)
  4. Journal of Investigative Dermatology (84)
  5. Modern Pathology (67)
  6. American Journal of Surgical Pathology (64)

More Publications

Publishers
  1. Springer (341)
  2. American Society of Clinical Oncology (284)
  3. Elsevier Inc. (231)
  4. Lippincott Williams & Wilkins (229)
  5. Wiley Blackwell (162)
  6. Elsevier Science, Inc. (160)

More Publishers

Results (2770)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Fertility post immune checkpoint blockade
    Meeting Abstract

    Ogle, M.; Harrold, E.; O'Brien, E.; Weiss, J. A.; Yaqubie, A.; Sinopoli, J. C.; Postow, M. A.; Cercek, A.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with advanced sarcoma: Results of expansion cohorts
    Meeting Abstract

    Kelly, C. M.; Avutu, V.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Movva, S.; Rosenbaum, E.; Cordover, E.; Ariyan, C. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Melanomas lacking HLA class I expression and response to checkpoint inhibitor
    Meeting Abstract

    Chapman, P. B.; Jayaprakasam, V. S.; Callahan, M. K.; Shoushtari, A. N.; Postow, M. A.; Lezcano, C.; Wolchok, J. D.; Nandakumar, S.; Chatila, W. K.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Population-based validation of the Melanoma Institute Australia (MIA) and the Memorial Sloan-Kettering Cancer Center (MSKCC) predictive tool for sentinel node status in patients with melanoma
    Meeting Abstract

    Mikiver, R.; Olofsson Bagge, R.; Marchetti, M. A.; Van Akkooi, A. C. J.; Coit, D. G.; Ingvar, C.; Isaksson, K.; Scolyer, R. A.; Thompson, J.; Varey, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Early ctDNA reduction may identify patients with stable disease and long OS on tebentafusp
    Meeting Abstract

    Feng, D.; Collins, L.; Callahan, M. K.; Sullivan, R. J.; Piperno-Neumann, S.; Nathan, P. D.; Hassel, J. C.; Goodall, H.; Holland, C.; Ranade, K.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Targeting AMP kinase in melanoma: A phase I trial of phenformin with dabrafenib/trametinib
    Meeting Abstract

    Chapman, P. B.; Klang, M.; Postow, M. A.; Shoushtari, A. N.; Sullivan, R. J.; Wolchok, J. D.; Wong, P.; Callahan, M. K.; Zippin, J.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • The effect of LNS8801 alone and in combination with pembrolizumab in patients with metastatic uveal melanoma
    Meeting Abstract

    Shoushtari, A. N.; Chaney, M. F.; Cohen, J. V.; Garyantes, T.; Lin, J. J.; Ishizuka, J. J.; Mita, A. C.; Mita, M. M.; Muller, C.; Natale, C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Final clinical results and first translational correlates of a phase 2 trial of adaptively dosed nivolumab and ipilimumab based on early radiographic assessment in advanced melanoma (ADAPT-IT)
    Meeting Abstract

    Smithy, J. W.; Kalvin, H. L.; Raber, V.; Maher, C. A.; Kleman, J.; McIntyre, D. A. G.; Shoushtari, A. N.; Betof Warner, A.; Callahan, M. K.; Momtaz, P.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Changes in PD-L1 and tumor mutational burden between paired samples and relationship to immune checkpoint inhibitor outcomes in non-small cell lung cancer
    Meeting Abstract

    Di Federico, A.; Alden, S. L.; Smithy, J. W.; Ricciuti, B.; Alessi, J. V. M.; Wang, X.; Pecci, F.; Gandhi, M. M.; Lamberti, G.; Spurr, L. F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • CD8 cell PET imaging with 89-Zr-crefmirlimab berdoxam (crefmirlimab) in patients with metastatic renal cell carcinoma (mRCC) receiving checkpoint inhibitors (CPIs): Association with response and tissue CD8 expression
    Meeting Abstract

    Pal, S. K.; Twardowski, P.; Chen, D. L.; Hall, E. T.; Hays, D.; Wilson, I.; Schmiedehausen, K.; Ferris, M.; Le, W.; Postow, M. A.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save